COMPANY PROFILE

Arbor Biotechnologies

Diverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – for accelerating the discovery of proteins for…

Cambridge, United StatesFounded 2016Biotech & Life Sciences

Valuation $1–2.5B Last recorded · 2025

Headcount 100–500 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Arbor Biotechnologies

Arbor Biotechnologies is an early-stage life sciences company at the forefront of biodiscovery. Leveraging cutting-edge technologies such as artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor is revolutionizing the discovery of proteins that can significantly improve human health and biotechnologies. The company is dedicated to developing curative genetic medicines for patients with serious genetic diseases by understanding the underlying genetic pathology of these conditions. Arbor's extensive toolbox of CRISPR-based genomic editors allows for tailored therapeutic approaches, unlocking advancements that have the potential to transform patient outcomes.

Read full description

Arbor primarily serves the healthcare sector, focusing on patients with genetic disorders. The company operates within the biotechnology market, utilizing a business model that centers on research and development partnerships, such as its collaboration with Vertex Pharmaceuticals to develop ex vivo engineered cell therapies. Arbor generates revenue through these strategic partnerships and the commercialization of its proprietary CRISPR technology.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Cambridge, United States
Employees: 103
Open positions: None listed
Dealroom signal: 63.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, DNA, Genetics and genomics, Core AI, Crispr, Spinout, Rumoured $1B
Technology: Artificial Intelligence, Deep Tech, Machine Learning, Nanotech
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Oct 2025	$0	—	Samsung Ventures	↗
SERIES COther financing	Mar 2025	$74M	$1.1B	Partners Investment · ArrowMark Partners · T. Rowe Price · Aberdeen	↗

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Arbor Biotechnologies website traffic

Latest recorded traffic for Arbor Biotechnologies is 8.1K monthly website visits, up 1.2% over the last three months. Arbor Biotechnologies's team declined 5.5% over the past year.

Latest monthly visits8.1K 3-month web change+1.2% 1-year team growth-5.5%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Director, Regulatory AffairsCambridge, MA · Other · Sep 2, 2026 Senior Clinical Trial ManagerCambridge, MA · Other · Aug 6, 2026 Manager, Regulatory AffairsCambridge, MA · Legal · Jul 26, 2026 Associate Director, Biomarker & Assay DevelopmentCambridge, MA · Other · Jul 11, 2026 Senior Scientist, PharmacologyCambridge, MA · Other · Jul 11, 2026

5 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DGDeep GenomicsDeep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies	Toronto, Canada	Operational	112	$237M	$720M
DTDyno TherapeuticsUtilizing next-gen DNA technologies and machine learning to engineer AAV capsids for effective delivery of gene therapies	Watertown, United States	Operational
CDC4X DiscoveryC4X Discovery - building the world's most productive drug discovery engine	Manchester, United Kingdom	Operational
MEMetagenomiDiscovering the next generation of gene-editing systems for use in treating genetic diseases	Emeryville, United States	Operational
SYSyntekabioAI driven drug discovery and development company	Seoul, South Korea	Operational
LTLodo TherapeuticsDrug discovery and development company	New York City, United States	Acquired
RPRecursion PharmaA clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery	Salt Lake City, United States	Operational
OPOppilotechComputational biology platform for first-in-class drug discovery	London, United Kingdom	Operational